📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
1 articles
AVG GRADE
NEUTRAL
score: 0.00
SENTIMENT
NEUTRAL
TOTAL VIEWS
9
ARFXF Latest News & AI Sentiment Analysis
1 articles · Grade: NEUTRAL · Real-time AI-graded coverage
RECENT COVERAGE · 3 ARTICLES
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
ProMIS Neurosciences released Q2 2026 earnings alongside interim data from its Phase 1b PRECISE-AD trial of PMN310, a therapeutic...
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
ProMIS Neurosciences announced interim safety results from its PMN310 Phase 1b trial for Alzheimer's disease, with no amyloid-related...
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
ProMIS Neurosciences (ARFXF) announced clinical validation of PMN310, its lead therapeutic candidate targeting amyloid-beta oligomers...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice